WILLIAM ROBERT LEVIS, M.D.
Medical Practice at 5 Ave, New York, NY
License number
New York 148755-1
Category
Medical Practice
Type
Specialist
Address
Address
166 5Th Ave FL 2, New York, NY 10010
Phone
(646) 915-4773
Personal information
See more information about WILLIAM ROBERT LEVIS at radaris.comName
Address
Phone
5062 45Th St #2NNDF, Flushing, NY 11377
4230 Douglaston Pkwy APT 5J, Little Neck, NY 11363
10 Waterside Plz APT 5K, New York, NY 10010
151 W 17Th St APT 5A, New York, NY 10011
182 Lincoln Rd, Brooklyn, NY 11225
Professional information
William R Levis, New York NY
Specialties:
Dermatology
Work:
Bellevue Hospital Center
462 1St Ave, New York, NY 10016
462 1St Ave, New York, NY 10016
Education:
University of Wisconsin at Madison (1964)
Gelled Immunomodulating Topical Compositions And A Method Of Treating Warts And Other Human Papilloma Virus Skin Infections
US Patent:
2006021, Sep 21, 2006
Filed:
Sep 16, 2005
Appl. No.:
11/228569
Inventors:
Leonard Kaplan - East Brunswick NJ, US
William Levis - New York NY, US
William Levis - New York NY, US
International Classification:
A61K 31/215, A61K 31/135, A61K 31/12, A61K 31/05
US Classification:
514529000, 514690000, 514646000, 514731000
Abstract:
Topical drug compositions of this invention contain delayed type contact sensitizing haptens in a unique non-flowable, non-toxic, non-volatile, anhydrous gel composition to achieve retained site application on warts and other human papilloma virus (HPV) skin infections. The preferred gelled compositions contain, but are not limited to, the sensitizing haptens, squaric acid dibutylester and diphenylcyclopropenone in optimized blends of Polysorbate 80, Isopropyl myristate uniquely gelled with Polyoxyl 40 stearate to form a penetrant of keratinized epitheliiuim of warts for direct application wherein virucidal pharlacologic action is induced by Th-1 cell mediated immune responses with resultant releases of CD4 helper T cells, CD8 killer T cells and cytokines to attack the human papilloma viruses. The commonly used vehicles with these contact sensitizers are acetone, petrolatum, or water containing emulsion creams which do not have the capacity to penetrate the keratinized wart surfaces and are therefore minimally effective in treating warts.
Topical Immune Competency Diagnostic Compositions And Methods Of Use
US Patent:
2005026, Nov 24, 2005
Filed:
May 20, 2004
Appl. No.:
10/849703
Inventors:
Leonard Kaplan - East Brunswick NJ, US
William Levis - New York City NY, US
William Levis - New York City NY, US
International Classification:
A61K049/00
US Classification:
424009600, 424009810
Abstract:
The compositions and methods of this invention are used to assess the level of immune competence of tested individuals based on the degree of immune response as a surrogate marker of CD4 T Cell lymphocytes as measured by the intensity of the resultant skin reaction score following controlled topical application of a unique anhydrous composition containing a contact sensitizer. The results of assessment are useful in determining appropriate treatment of immuno-compromised patients. Preferred compositions contain, but are not limited to, Diphenylcyclpropenone as a preferred embodiment of the class of contact sensitizing agents applied to the skin in an optimally prepared formulation preferably containing about 0.4% of the contact sensitizer.
Heat Shock Proteins From Mycobacterium Leprae And Uses Thereof
US Patent:
2010013, Jun 3, 2010
Filed:
Nov 23, 2009
Appl. No.:
12/624288
Inventors:
William R. LEVIS - New York NY, US
Frank T. MARTINIUK - Wood-Ridge NJ, US
Frank T. MARTINIUK - Wood-Ridge NJ, US
Assignee:
NEW YORK UNIVERSITY - New York NY
International Classification:
A61K 38/16, A61K 39/04, C07H 21/04, C07K 14/35, C07K 16/12, A61P 35/00, A61P 31/08, A61P 17/00, A61P 27/14, C12N 5/10, C12N 1/21, C12N 7/00, A61K 39/395, G01N 33/53, C12Q 1/68
US Classification:
4241391, 4241901, 514 12, 536 237, 530350, 536 234, 5303879, 435325, 4352523, 4352351, 4352542, 435348, 435419, 435 71, 435 6
Abstract:
The present invention is directed to heat shock proteins from as well as their encoding polynucleotides and vectors and host cells containing these polynucleotides. These heat shock proteins and their encoding polynucleotides are useful in detection of . In addition, the heat shock protein can be used as an adjuvant in a pharmaceutical composition containing an antigen to induce or enhance the immune response against the antigen. Further, the heat shock protein may be used to treat atopic conditions or as a vaccine against . Alternatively, the heat shock protein can be used to form a fusion protein with an antigen to induce or enhance the immune response against the antigen.
Effective Sensitizing Dose Of A Gelled Immunomodulating Topical Composition
US Patent:
2011026, Nov 3, 2011
Filed:
Feb 25, 2011
Appl. No.:
13/035692
Inventors:
William R. Levis - New York NY, US
Leonard L. Kaplan - East Brunswick NJ, US
John G. Callahan - Moorestown NJ, US
Leonard L. Kaplan - East Brunswick NJ, US
John G. Callahan - Moorestown NJ, US
International Classification:
A61K 39/12, A61P 35/00, A61P 31/20, A61K 31/122, A61P 17/12
US Classification:
4242041, 514683
Abstract:
The present invention relates to compositions and methods of treating warts and other human papilloma virus (HPV) skin infections. The present invention relates to compositions and methods of treating skin cancer.
Heat Shock Proteins From And Uses Thereof
US Patent:
7622121, Nov 24, 2009
Filed:
Sep 19, 2006
Appl. No.:
11/523215
Inventors:
William R. Levis - New York NY, US
Frank T. Martiniuk - Wood-Ridge NJ, US
Frank T. Martiniuk - Wood-Ridge NJ, US
Assignee:
New York University - New York NY
International Classification:
A61K 39/02, A61K 39/38, A61K 45/00, A61K 47/00
US Classification:
4241901, 4241841, 4242781, 4242811, 4242821
Abstract:
The present invention is directed to heat shock proteins from as well as their encoding polynucleotides and vectors and host cells containing these polynucleotides. These heat shock proteins and their encoding polynucleotides are useful in detection of. In addition, the heat shock protein can be used as an adjuvant in a pharmaceutical composition containing an antigen to induce or enhance the immune response against the antigen. Further, the heat shock protein may be used to treat atopic conditions or as a vaccine against. Alternatively, the heat shock protein can be used to form a fusion protein with an antigen to induce or enhance the immune response against the antigen.